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ABSTRACT OF THESIS

RELATIONSHIP BETWEEN INITIAL PRESCRIPTION OPIOID EXPOSURE
LENGTH AND FUTURE OPIOID USE DISORDER DIAGNOSIS
IN OPIOID NAÏVE ADOLESCENTS
Objectives: The long-term risks associated with the use of short-term prescription
opioids in opioid naïve adolescents in not well characterized. The purpose of this study
was to explore the potential association between the days’ supply of the initial
prescription opioid exposure and the rates of diagnosed OUD in the subsequent 3-year
period. Methods: We conducted a retrospective cohort study using a nationwide database
of commercially-insured adolescents aged 12-17 at the time of the index opioid fill. A
multivariable Cox Proportional Hazard regression model was developed to analyze the
association of interest while accounting for known risk factors for the development of
OUD. Results: Results of the Cox Proportional Hazard analysis showed no significant
differences in the risks of future OUD diagnosis between any of the days’ supply groups.
Conclusions: In this commercially-insured, opioid naïve adolescent population, there was
no significant association between the days’ supply of the initial opioid prescription the
rate of OUD diagnosis in the subsequent 3-year period.
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CHAPTER 1. INTRODUCTION
As the opioid crisis continues to grip the nation, there remains a need to better
understand the risks of opioid use and the pathways that lead to opioid use disorder (OUD).
OUD, previously classified as ‘opioid abuse’ or ‘opioid dependence’, is a mental disorder
included in the most recent Diagnostic and Statistical Manual of Mental Disorders (DSM5).1 It is defined by the American Psychiatric Association as ‘a problematic pattern of
opioid use that causes significant impairment or distress’.2 Diagnosis is based on an 11
point questionnaire about characteristics of opioid use, lifestyle impact, and indicators of
opioid tolerance and withdrawal.1 The presence of two indicators qualifies a patient for a
OUD diagnosis, with ‘mild’ severity. ‘Moderate’ and ‘severe’ OUD diagnoses occur with
the presence of four and six indicators respectively.3 OUD affects a significant number of
people in the United States, as well as the rest of the world. According to the U.S. Centers
for Disease Control and Prevention (CDC), an estimated 2.1 million Americans had OUD
in 2016.2 An OUD diagnosis is associated with an increase in the rates of patient morbidity
and mortality. Patients with OUD have higher rates of acute hospitalization, emergency
department visits, and opioid related complications, as well as increased healthcare costs.4,5
The risk of death is also significantly increased, with mortality rates up to 20 times higher
than that of the general population.6 Furthermore, patients with OUD who use opioids
intravenously place themselves at increased risk for serious comorbidities such as bacterial
endocarditis, HIV, and hepatitis.4
It has been found that many patients with OUD had their initial exposure to opioids
through opioids prescribed to them by a medical professional, often for acute pain.7,8 As
the risks of prescription opioid use became better understood, there were increased efforts
to develop guidelines aimed at reducing opioid prescribing. This focus has led to reductions
in the amount of prescription opioids dispensed. Since 2011, there has been an estimated
43% decrease in opioid analgesic prescription volume, in morphine milligram equivalents
(MME). However, these medications continue to be widely prescribed and their use
remains well above pre-2000 levels.9,10

The CDC estimates there were 58 opioid

prescriptions written per 100 Americans in 2017, with 46 people dying every day from
prescription opioid-related overdoses.11,12 Additionally, the IQVIA Institute estimates that
1

acetaminophen/hydrocodone combination medications were the fifth most dispensed class
of medications the US in 2018.10 These statistics indicate that opioid use in the United
States is still high, and reiterate the importance of finding ways to reduce the incidence of
OUD and opioid-related harm.
Many patient characteristics have been shown to predispose a patient to developing
OUD. A history of a substance use disorder (SUD) and certain mental health diagnoses,
such as psychotic disorders, personality disorders and anxiety disorders, are associated with
an increased risk of developing OUD.6,13 Additionally, indicators of economic
disadvantage have also been associated with the development of OUD, including a lack of
insurance, unemployment, and income.14 Furthermore, male gender, Caucasian ethnicity,
age at first opioid exposure, single marital status, and poor self-reported health have also
been associated with OUD.13,15–18 Genetics may also play a role in predisposition to OUD,
however this is less well understood.19
It is also important to understand the characteristics of the initial opioid exposure that
are associated with OUD, and possible indicators of OUD such as the transition from acute
to chronic use. Since many patients with OUD were initially exposed to opioids through a
legitimate prescription, these correlations are important in developing clinical guidelines
and best practices.20 Various prescription characteristics have been associated with long
term opioid use and OUD, including higher daily opioid dose (in Morphine Milligram
Equivalents; MME), the use of long acting or extended release opioids, refill count, and
increasing days’ supply of the initial prescription.13,20–24 Interestingly, multiple
retrospective studies have found that the length of the initial opioid prescription was a more
important factor than opioid dose when predicting the risk of future OUD.8,21,25 Guidelines
from the CDC suggest that treatment durations of 3 days or less will often be sufficient to
treat acute pain, with treatment durations of 7 days or more rarely being necessary.20,26
Other research suggests that the risks of transitioning from acute to chronic opioid use
begin to increase starting with the third day of opioid therapy, and rise sharply after the
fifth and thirty first days of therapy.27
While an increasing duration of the initial opioid prescription may increase the risk of
developing OUD, shorter prescriptions may still pose significant risk. It is known that
2

prolonged opioid exposure puts patients at risk for OUD due to the risks of physical
dependence, which increase sharply after 5 days of exposure.20 However, initial opioid
exposures of less than 5 days may also place patients at risk of future OUD, but for a
different reason. Regardless of the length of the initial exposure, the prescribed opioid may
be a patient’s first experience with a mind-altering drug. The pleasurable feelings
associated with opioids may cause patients to seek out these drugs, despite a lack of
physical dependence. It has been found that adolescents with little to no prior experience
with illicit drugs are at an increased risk for future opioid misuse, when compared to their
peers with prior exposure.28 This seems to support the idea that the mind-altering effects
of the opioid may be more profound in those with no prior exposure to mind altering drugs.
It has also been found that the risks of future opioid misuse may be higher in adolescents
who, at baseline, strongly disapprove of illegal drug use.28 While these patients may avoid
exposure to opioids via illicit means, this barrier to is removed when the initial exposure is
via a legitimate prescription. This widens the spectrum of at-risk patients to include those
who would not otherwise have been exposed to opioids. This data provides evidence for
the claim that all lengths of initial exposures may be dangerous, but the reasoning for the
transition to OUD may differ based on the length of the initial exposure.
Adolescents (aged 12-17) are a subset of the population that is often exposed to opioids
as well. Adolescents commonly experience procedures in which opioids are commonly
prescribed, such as dental work, surgery, and sports injuries, which may place them at
higher risk for opioid related problems in the future.29–33 By high school graduation, an
estimated 25% of adolescents have been exposed to prescription opioids through either
medical or nonmedical means.34 No other illicit substance is abused more prevalently in
the 12-17 age group, aside from marijuana.35 While adolescents share many of the same
OUD risk factors with adults, factors such as prior exposure to illicit substances,
motivations for opioid use, social pressures, and neurologic development may differ
between the two groups. Therefore, it is important to study these populations separately.
As mentioned previously, a lack of prior exposure to mind altering substances may
predispose patients to future OUD, even after a single opioid exposure. This risk may
disproportionately affect adolescents, as they are less likely to have prior experience with
illicit substances or alcohol. Another difference between adults and adolescents are the
3

varying motivations for using opioids nonmedically. One survey based study found that
adults were 42% more likely than adolescents to report abusing opioids in an attempt to
relieve physical pain.14 In contrast, another survey based study found that high school
seniors were more likely to report using opioids nonmedically to ‘relax’ or ‘get high.’36
Additionally, the decision-making systems of the adolescent brain are less developed than
those in adults. While the areas of the brain that handle feelings of reward and pain are
well developed by the time of adolescence, the areas involved in decision-making and
judgement are not fully developed until the mid-twenties.37 Since the reward system of the
adolescent brain is intimately involved in drug use, this differentiates them from adults.
These factors, coupled with the extensive peer pressure and desire to fit in, could affect the
transition from opioid use to OUD in adolescents.37
Both governmental and non-governmental bodies have recognized the potential link
between days’ supply and the risks of chronic opioid use and future OUD and have worked
to place limits on the length of initial opioid prescriptions. Since 2016 when the first
legislation was passed in Massachusetts, at least 33 states have adopted some type of opioid
prescription limitations.38 The legislation varies in the method used to restrict initial opioid
prescriptions. Methods include limiting the days’ supply, limiting the maximum opioid
dose (MME), and directing other entities to develop these limitations (such as a state health
organization or provider regulatory board). Most commonly, legislation creates statutory
limits on the maximum days’ supply of the initial opioid prescription. These limits vary
between 3 and 14 days, with the most common days’ supply limit being 7 days.38 Nongovernmental organizations have also implemented policies to restrict the days’ supply of
the initial opioid fill, with both CVS and Walmart restricting the filling of initial acute
opioid prescriptions to a 7 day supply.39,40 Despite these limitations, there are often
exceptions to these rules, such as the treatment of chronic pain, cancer, or palliative care.38
Additionally, these restrictions can often be overruled based on the professional judgement
of the provider, often requiring explicit documentation of the exception in the patient’s
medical record. Some states have also taken steps to further limit access to opioids by
adolescents, and have developed limits specifically for this population.38 These laws may
extend limits on opioid prescriptions beyond the initial fill, or include other requirements
such as mandatory counseling of the minor and/or guardian on the risks of opioid use.
4

Due to the relatively new implementation of these laws, it is too early to tell which
days’ supply limit, if any, will lead to reductions in OUD. It is also unclear which days’
supply, if any, increases an adolescent’s risk for developing OUD. As more states move to
implement these laws, further research into the effect of days’ supply on the risks of future
OUD can help inform policymakers on overall effective approaches and whether or not the
adolescent population should be treated differently than adults when considering such
legislation.
While there is research describing potential factors influencing the risks of future OUD
in adolescents, the effect of days’ supply is less well understood. The majority of studies
looking at this age group utilize self-reported questionnaires or geographically
homogenous populations. Furthermore, relevant studies that do utilize claims data to study
long term opioid misuse do not focus specifically on the adolescent population. Further
analysis of this topic using nationwide claims data may help better inform
recommendations on limiting the length of OUD prescriptions in adolescents. The main
objective of this study is to determine if there is an association between the days’ supply
of the index opioid fill and the rate of future OUD diagnosis in adolescents. We hypothesize
that the rates of diagnosed OUD will begin to significantly increase in patients receiving
an index opioid prescription of longer than 7 days. Secondary objectives for this study are
to determine the prevalence of OUD diagnosis in the population, the average MME per day
of the index prescription, and the average days’ supply of the initial prescription. These
statistics will help better describe characteristics of the initial opioid exposure in this
population.

5

CHAPTER 2. METHODS
2.1

Data Source
This study used deidentified health claims from a large commercially insured

population of about 23 million patients for the period of 2008-2017. Patients are
demographically representative of the US population with respect to gender and age, and
representative of the commercially-insured population on all other measurable
characteristics.

2.2

Study Population
All patients with the following characteristics were included in the analysis: (1) at

least one opioid prescription between January 1st 2008 and December 31st 2017 as
identified using Generic Product Identifier (GPI) codes beginning with ‘65’ (2) at least 6
months of continuous enrollment without an opioid prescription before the index fill, and
(3) between the ages of 12 and 17 at the time of the index opioid prescription. Patients with
the following characteristics were excluded from the analysis: (1) patients whose first
prescription was for a buprenorphine product, (2) patients with a cancer diagnosis in the 6
month lookback period, (3) patients whose first opioid fill was for a Schedule V opioid, (4)
patients with a diagnosis of OUD prior to their first opioid fill, (5) patients with an initial
opioid prescription days’ supply of more than 14 days, and (6) patients whose demographic
information was incomplete or invalid. Patients whose index opioid fill was for a
buprenorphine product were excluded from the analysis as buprenorphine containing
medications are often used in the treatment of OUD. While buprenorphine containing
products have demonstrated some efficacy in the treatment of pain, their use is widely
popular in medication assisted treatment (MAT) for OUD.41 To avoid the possibility of
the results being affected by missing or incorrectly coded OUD diagnoses, these patients
were excluded from the analysis. Consistent with other studies, patients with a cancer
diagnosis in the 6-month lookback period were also excluded. Patients whose index opioid
fill was for a Schedule V opioid were excluded from the analysis as this class of opioids,
which includes medications such as atropine-diphenoxylate and low potency codeinecontaining cough syrups, are typically used to treat conditions other than pain. Finally,
6

since the focus of this study is the effects of acute opioid exposure, patients with initial
prescriptions of longer than 14 days were excluded.

2.3

Outcome
Patients were followed from the date of their first opioid prescription until

insurance disenrollment, OUD diagnosis, 3 years of continuous follow up, or the end of
the dataset period, whichever came first (Figure 2.1). Consistent with previous studies,
OUD was defined as a patient with any ICD-9 or ICD-10 diagnosis code for opioid
dependence or opioid abuse in any diagnosis field of the claim (Appendix A).8
Using the days’ supply of the first prescription opioid fill, patients were divided
into categories based on common days’ supply limitations enacted by states (1-3 days, 3-4
days, 5-7 days, and 8-14 days). MME per day was calculated by multiplying the daily dose
(in milligrams) of the prescription by the MME conversion factor. Conversion factors were
gathered from the Centers for Medicare and Medicaid Services (CMS).42 A conversion
factor for propoxyphene-containing products was not included in the resource from CMS,
and was gathered from another source.43 90 MME per day was chosen as the cutoff for a
‘high dose’ opioid, to create a binary variable for inclusion into the statistical model. This
threshold was chosen based on the CDC’s recommendation that dosages over 90 MME/day
should be avoided, as they can increase the risk of an opioid overdose death by a factor of
ten.7,44 To account for patients with comorbid psychiatric conditions that could predispose
them to OUD, a binary variable was created for the presence of these conditions. A search
was performed for psychotic, anxiety, and personality disorders using ICD-9 and ICD-10
diagnosis (Appendix B). If the patient was found to have a diagnosis code for any of these
conditions during the study period, they were included in the psychiatric subgroup.

2.4

Statistical Analysis
A multivariable Cox-proportional hazard regression model was developed to

determine the association between the days’ supply of the index opioid prescription on the
likelihood of an OUD diagnosis in the subsequent 3 year (1,095 days) follow up period.
Covariates for the days’ supply group, age at index opioid fill, gender, race, MME per day,
7

socioeconomic status, and presence of comorbid psychiatric disorders were included in the
model. These covariates were chosen due to their previously described association with
OUD. All analyses were conducted using SAS version 9.4 (SAS Institute, Cary NC). Since
this study utilized de-identified patient data, institutional review board approval was not
required.

8

Figure 2.1: Study Timeline
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CHAPTER 3. RESULTS
3.1

Demographics
After applying inclusion and exclusion criteria, 284,514 patients who met study

criteria were identified (Figure 3.1). Table 3.1 provides a summary of patient
demographics. Patients were an average of 15.3 (1.58) years of age and similarly divided
by gender. Patients in the 16-17 age group accounted for 156,723 (55.1%) of opioid
prescriptions. The vast majority (79.6%) were white and 13.4% had a psychiatric disorder
diagnosis. Table 3.2 summarizes the characteristics of index opioid prescriptions. The two
most common opioids found in the index prescriptions were hydrocodone and codeine
containing products, which accounted for 174,484 (61.3%) and 51,337 (18.0%) of
prescriptions, respectively. Prescriptions of 3 days were the most common in the study
population, accounting for 79,459 (27.9%) of prescriptions. After assignment into groups
based on the days’ supply of the initial prescription, the most common category was 1-3
days, which accounted for 180,326 (63.4%) patients. The least common category was 8-14
days, which accounted for only 20,647 (7.3%) of prescriptions. The average daily dose of
the index opioid fills was 37.1 ( 21.8) MME with few (3.5%) dispensed that were over 90
MME daily. Overall, during the 3 year follow up period, OUD was diagnosed in 423
(0.15%) patients in the study population. Among patients who were diagnosed with OUD
within 3 years of their index opioid fill, the mean time to diagnosis was 473 days (~1.3
years).

3.2

Statistical Analysis
Results of the Cox Proportional Hazard analysis (Table 3.3) showed no significant

differences in the risks of future OUD diagnosis between any of the days’ supply groups.
As expected, male gender, increasing age, and the presence of psychiatric disorder
diagnoses were associated with increased risk of an OUD diagnosis within 3 years of the
index opioid fill. No significant differences in the risk of future OUD diagnosis was seen
among race, year of index opioid fill, indicators of income, or whether or not the daily
MME was considered ‘high dose’. Survival curves were generated for overall survival
(Figure 3.2) and survival stratified by days’ supply group (Figure 3.3).
10

Table 3.1: Patient Demographics (n=284,514)
Characteristic

Overall
Value (%)
284,514

Patient Count
Gender
Male
144,216 (50.7)
Female
140,298 (49.3)
Race
White
226,481 (79.6)
Hispanic
26,373 (9.3)
Black
23,322 (8.2)
Asian
8,338 (2.9)
Household Income
> 400% Poverty Line 282,695 (99.4)
< 400% Poverty Line
1,819 (0.6)
Psychiatric Disorder Diagnosis
No
246,428 (86.6)
Yes
38,086 (13.4)
OUD Diagnosis During Study
Yes
423 (0.15)
No
284,091 (99.9)

1-3 Days
Value (%)
180,326 (63.4)

4-5 Days
Value (%)
59,255 (20.8)

6-7 Days
Value (%)
24,286 (8.5)

8-14 Days
Value (%)
20,647 (7.3)

90,214 (62.6)
90,112 (64.2)

30,741 (21.3)
28,514 (20.3)

12,582 (8.7)
11,704 (8.3)

10,679 (7.4)
9,968 (7.1)

144,713 (63.9)
15,986 (60.6)
14,265 (61.2)
5,362 (64.3)

46,758 (20.7)
5,810 (22.0)
4,975 (21.3)
1,712 (20.5)

18,880 (8.3)
2,469 (9.4)
2,190 (9.4)
747 (9.0)

16,130 (7.1)
2,108 (8.0)
1,892 (8.1)
517 (6.2)

179,191 (63.4)
1,135 (62.4)

58,866 (20.8)
389 (21.4)

24,123 (8.5)
163 (9.0)

20,515 (7.3)
132 (7.3)

155,866 (63.3)
24,460 (64.2)

51,620 (21.0)
7,635 (20.1)

21,098 (8.6)
3,188 (8.4)

17,844 (7.2)
2,803 (7.4)

282 (66.7)
180,044 (63.4)

80 (18.9)
59,175 (20.8)

30 (7.1)
24,256 (8.5)

31 (7.3)
20,616 (7.3)
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Table 3.2: Index Opioid Fill Characteristics (n=284,514)
Characteristic
Value
Percent (%)
Days’ Supply
1-3 days
180,326
63.4
4-5 days
59,255
20.8
6-7 days
24,286
8.5
8-14 days
20,647
7.3
Daily MME
< 90
274,580
96.5
90+
9,917
3.5
Most Prevalent Opioids
Hydrocodone/Acetaminophen 171,530
60.3
Codeine/Acetaminophen
51,103
18.0
Oxycodone/Acetaminophen
36,322
12.8
Tramadol HCl
8,505
3.0
Oxycodone HCl
5,947
2.1
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Table 3.3: Cox-proportional Hazard Regression Model Results (n=284,514)
Characteristic
Hazard Ratio
95% CI
Days’ Supply Group
1-3
Ref
4-5
0.959
0.710 – 1.208
6-7
0.923
0.546 – 1.300
8-14
1.234
0.862 – 1.606
Daily MME
< 90 MME
Ref
90+ MME
0.825
0.290 – 1.360
Gender
Female
Ref
Male
2.15a
1.950 – 2.350
Age Group
12-13
Ref
a
14-15
3.315
2.782 – 3.848
16-17
5.572a
5.249 – 6.255
Race
White
Ref
Asian
0.569
-0.239 – 1.377
Black
0.875
0.483 – 1.267
Hispanic
0.661
0.255 – 1.067
Household Income
> 400% Poverty Line
Ref
< 400% Poverty Line
1.376
0.238 – 2.514
Psychiatric Disorder Diagnosis
No
Ref
a
Yes
10.635
10.434 – 10.836
a
Statistically Significant with p < 0.05

13

Figure 3.1: Patient Exclusion Flowchart
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Figure 3.2: Overall Survival Curve (n=423)
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Figure 3.3: Survival Curve Stratified by Days’ Supply of the Index Opioid Prescription
(n=284,514)
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CHAPTER 4. DISCUSSION
4.1

Discussion of Results
In this study of 284,414 privately insured, opioid naïve U.S. adolescents, no

association was found between the days’ supply of the index opioid prescription and the
risk of OUD diagnosis in the subsequent 3-year period. Even for prescriptions of less than
3 days, thought to be too short to cause physical dependence, the risk of future OUD
diagnosis is not significantly lower than prescriptions of 8-14 days. While no other study
has found an association between days’ supply and future OUD diagnosis in adolescents,
other studies have found links between days’ supply and surrogates of OUD, such as opioid
overdose and a transition to long term opioid use. One study of 1.3 million privately insured
patients 14 years and older found that the probability of continued opioid use increases
steadily with the days’ supply of the initial opioid fill, with days’ supplies up to >22 days.
The study found that, when compared to initial prescriptions of 2 days or less, prescriptions
of 5-7 days and 8-10 days increased the chances of long term opioid use by a factor of three
and a factor of five, respectively.

8

A second study found a substantial increase in the

probability of continued opioid use in opioid naïve adults once the days’ supply of the
initial prescription reached 6 days, with another substantial increase after 10 days.27 A third
study looking at post-surgical opioid naïve adults found that each additional week of opioid
supply increased the risk of future opioid misuse by 20%.45
While this finding does not give specific guidance on days’ supply limits to states
considering statutory limitations on initial opioid prescriptions, these findings may support
the consideration of differing limitations on adolescents compared to adults. While other
studies in adults show that the risk of OUD diagnoses may increase with days’ supply, this
data does not support that in adolescents. Rather, it shows that a shorter days’ supply is no
‘safer’ than a longer days’ supply in adolescents. While all medications should be
prescribed for the lowest possible dose for the shortest duration, prescribers should remain
especially cognizant of this for opioids given the state of the opioid epidemic.
Consistent with previous literature, the results also showed that male gender,
increased age at exposure, and comorbid psychiatric disorders were associated with an
17

increased incidence of OUD. In contrast to previous studies, no increase in the incidence
of OUD diagnosis was seen in regard to race or indicators of socioeconomic status. High
dose opioids (90+ MME) were also not found to increase the risk of a future OUD
diagnosis. The findings of OUD diagnosis rates (0.15%) and time to OUD diagnosis (~1.3
years) in this study were lower when compared to a prior study of opioid naïve patients in
the post-surgical setting. The study included 146,556 patients age 24 and under, in which
opioid misuse was subsequently identified in 0.22% of patients <15 years of age, and
1.25% in patients aged 15-24. The mean time to opioid misuse was 2.39 years in patients
<15 years old, and 1.47 years in patients 15-24.45

4.2

Limitations
Several limitations must be considered when interpreting these results. First, no

control group containing patients without an opioid exposure was included in this study.
Due to the difficulty in accounting for the multitude of risk factors that may vary between
opioid users and non-opioid users, this element was not pursued in this analysis. The
absence of this control group means the baseline rate of OUD diagnosis is unable to be
determined in this cohort. Secondly, this dataset only included commercially insured
patients. Therefore, uninsured patients and patients covered under Medicaid were not
included in this analysis, leaving out a large proportion of opioid users with many risk
factors for OUD. Additionally, this study relies on medical coding for OUD diagnosis
information and comorbid condition identification, both during the study period and the
six-month lookback period. Errors or omissions common with medical coding could affect
the results. Due to the nature of claims data, it is impossible to determine if the medications
were taken as directed, or even taken at all. Also, prescriptions not run through insurance
would not be captured in this dataset. Additionally, this study did not consider
characteristics of opioid exposures other than the index fill. This could lead to inter-patient
variability in subsequent opioid exposures, which could affect the risks of OUD diagnosis.
Also, while this study incorporated a six-month lookback period, a patient may have been
exposed to opioids prior to this lookback period, meaning the patient would not truly be
opioid naïve. Pain etiology and a patient’s history of other substance use disorders were

18

also not included in this analysis, and this information has been shown to affect the risks
of OUD.

4.3

Conclusions
In this commercially-insured, opioid naïve adolescent population, there was no

significant association between the days’ supply of the initial opioid prescription the rate
of OUD diagnosis in the subsequent 3-year period. This data suggests that the risk of
future OUD for initial opioid exposures of 1-3 days, thought to be too short to induce
physical dependence, are not significantly different than prescriptions lengths of up to 14
days. Extra caution should be taken when prescribing opioids of any duration, especially
in patients who are male, older adolescents, and/or have comorbid psychiatric conditions.

19

APPENDICES

Appendix A: Diagnosis Codes for Opioid Use Disorder
304.00
304.01
304.02
304.03
304.70
304.71
304.72
304.73
305.50
305.51
305.52
305.53
F11.10
F11.120
F11.121
F11.122
F11.129
F11.14
F11.150
F11.151
F11.159
F11.181
F11.182
F11.188
F11.19
F11.20
F11.21
F11.220
F11.221
F11.222
F11.229
F11.23
F11.24
F11.250
F11.251
F11.259
F11.281
F11.282
F11.288
F11.29
F11.90
F11.920
F11.921

Opioid type dependence, unspecified
Opioid type dependence, continuous
Opioid type dependence, episodic
Opioid type dependence, in remission
Combinations of opioid type drug with any other drug dependence, unspecified
Combinations of opioid type drug with any other drug dependence, continuous
Combinations of opioid type drug with any other drug dependence, episodic
Combinations of opioid type drug with any other drug dependence, in remission
Opioid abuse, unspecified
Opioid abuse, continuous
Opioid abuse, episodic
Opioid abuse, in remission
Opioid abuse, uncomplicated
Opioid abuse with intoxication, uncomplicated
Opioid abuse with intoxication delirium
Opioid abuse with intoxication with perceptual disturbance
Opioid abuse with intoxication, unspecified
Opioid abuse with opioid-induced mood disorder
Opioid abuse with opioid-induced psychotic disorder with delusions
Opioid abuse with opioid-induced psychotic disorder with hallucinations
Opioid abuse with opioid-induced psychotic disorder, unspecified
Opioid abuse with opioid-induced sexual dysfunction
Opioid abuse with opioid-induced sleep disorder
Opioid abuse with other opioid-induced disorder
Opioid abuse with unspecified opioid-induced disorder
Opioid dependence, uncomplicated
Opioid dependence, in remission
Opioid dependence with intoxication, uncomplicated
Opioid dependence with intoxication delirium
Opioid dependence with intoxication with perceptual disturbance
Opioid dependence with intoxication, unspecified
Opioid dependence with withdrawal
Opioid dependence with opioid-induced mood disorder
Opioid dependence with opioid-induced psychotic disorder with delusions
Opioid dependence with opioid-induced psychotic disorder with hallucinations
Opioid dependence with opioid-induced psychotic disorder, unspecified
Opioid dependence with opioid-induced sexual dysfunction
Opioid dependence with opioid-induced sleep disorder
Opioid dependence with other opioid-induced disorder
Opioid dependence with unspecified opioid-induced disorder
Opioid use, unspecified, uncomplicated
Opioid use, unspecified with intoxication, uncomplicated
Opioid use, unspecified with intoxication delirium

20

F11.922
F11.929
F11.93
F11.94
F11.950
F11.951
F11.959
F11.981
F11.982
F11.988
F11.99

Opioid use, unspecified with intoxication with perceptual disturbance
Opioid use, unspecified with intoxication, unspecified
Opioid use, unspecified with withdrawal
Opioid use, unspecified with opioid-induced mood disorder
Opioid use, unspecified with opioid-induced psychotic disorder with delusions
Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations
Opioid use, unspecified with opioid-induced psychotic disorder, unspecified
Opioid use, unspecified with opioid-induced sexual dysfunction
Opioid use, unspecified with opioid-induced sleep disorder
Opioid use, unspecified with other opioid-induced disorder
Opioid use, unspecified with unspecified opioid-induced disorder
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Appendix B: Diagnosis Codes for Psychiatric Disorders
Psychotic Disorders
295.00
Simple type schizophrenia, unspecified
295.01
Simple type schizophrenia, subchronic
295.02
Simple type schizophrenia, chronic
295.03
Simple type schizophrenia, subchronic with acute exacerbation
295.04
Simple type schizophrenia, chronic with acute exacerbation
295.05
Simple type schizophrenia, in remission
295.10
Disorganized type schizophrenia, unspecified
295.11
Disorganized type schizophrenia, subchronic
295.12
Disorganized type schizophrenia, chronic
295.13
Disorganized type schizophrenia, subchronic with acute exacerbation
295.14
Disorganized type schizophrenia, chronic with acute exacerbation
295.15
Disorganized type schizophrenia, in remission
295.20
Catatonic type schizophrenia, unspecified
295.21
Catatonic type schizophrenia, subchronic
295.22
Catatonic type schizophrenia, chronic
295.23
Catatonic type schizophrenia, subchronic with acute exacerbation
295.24
Catatonic type schizophrenia, chronic with acute exacerbation
295.25
Catatonic type schizophrenia, in remission
295.30
Paranoid type schizophrenia, unspecified
295.31
Paranoid type schizophrenia, subchronic
295.32
Paranoid type schizophrenia, chronic
295.33
Paranoid type schizophrenia, subchronic with acute exacerbation
295.34
Paranoid type schizophrenia, chronic with acute exacerbation
295.35
Paranoid type schizophrenia, in remission
295.40
Schizophreniform disorder, unspecified
295.41
Schizophreniform disorder, subchronic
295.42
Schizophreniform disorder, chronic
295.43
Schizophreniform disorder, subchronic with acute exacerbation
295.44
Schizophreniform disorder, chronic with acute exacerbation
295.45
Schizophreniform disorder, in remission
295.50
Latent schizophrenia, unspecified
295.51
Latent schizophrenia, subchronic
295.52
Latent schizophrenia, chronic
295.53
Latent schizophrenia, subchronic with acute exacerbation
295.54
Latent schizophrenia, chronic with acute exacerbation
295.55
Latent schizophrenia, in remission
295.60
Schizophrenic disorders, residual type, unspecified
295.61
Schizophrenic disorders, residual type, subchronic
295.62
Schizophrenic disorders, residual type, chronic
295.63
Schizophrenic disorders, residual type, subchronic with acute exacerbation
295.64
Schizophrenic disorders, residual type, chronic with acute exacerbation
295.65
Schizophrenic disorders, residual type, in remission
295.70
Schizoaffective disorder, unspecified
295.71
Schizoaffective disorder, subchronic
295.72
Schizoaffective disorder, chronic
295.73
Schizoaffective disorder, subchronic with acute exacerbation
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295.74
Schizoaffective disorder, chronic with acute exacerbation
295.75
Schizoaffective disorder, in remission
295.80
Other specified types of schizophrenia, unspecified
295.81
Other specified types of schizophrenia, subchronic
295.82
Other specified types of schizophrenia, chronic
295.83
Other specified types of schizophrenia, subchronic with acute exacerbation
295.84
Other specified types of schizophrenia, chronic with acute exacerbation
295.85
Other specified types of schizophrenia, in remission
295.90
Unspecified schizophrenia, unspecified
295.91
Unspecified schizophrenia, subchronic
295.92
Unspecified schizophrenia, chronic
295.93
Unspecified schizophrenia, subchronic with acute exacerbation
295.94
Unspecified schizophrenia, chronic with acute exacerbation
295.95
Unspecified schizophrenia, in remission
297.0
Paranoid state, simple
297.1
Delusional disorder
297.2
Paraphrenia
297.3
Shared psychotic disorder
297.8
Other specified paranoid states
297.9
Unspecified paranoid state
298.0
Depressive type psychosis
298.1
Excitative type psychosis
298.2
Reactive confusion
298.3
Acute paranoid reaction
298.4
Psychogenic paranoid psychosis
298.8
Other and unspecified reactive psychosis
298.9
Unspecified psychosis
F20.0
Paranoid schizophrenia
F20.1
Disorganized schizophrenia
F20.2
Catatonic schizophrenia
F20.3
Undifferentiated schizophrenia
F20.5
Residual schizophrenia
F20.81
Schizophreniform disorder
F20.89
Other schizophrenia
F20.9
Schizophrenia, unspecified
F21
Schizotypal disorder
F22
Delusional disorders
F23
Brief psychotic disorder
F24
Shared psychotic disorder
F25.0
Schizoaffective disorder, bipolar type
F25.1
Schizoaffective disorder, depressive type
F25.8
Other schizoaffective disorders
F25.9
Schizoaffective disorder, unspecified
F28
Other psychotic disorder not due to a substance or known physiological condition
F29
Unspecified psychosis not due to a substance or known physiological condition
Anxiety Disorders
300.00
Anxiety state, unspecified
300.01
Panic disorder without agoraphobia
300.02
Generalized anxiety disorder
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300.09
Other anxiety states
300.10
Hysteria, unspecified
300.11
Conversion disorder
300.12
Dissociative amnesia
300.13
Dissociative fugue
300.14
Dissociative identity disorder
300.15
Dissociative disorder or reaction, unspecified
300.16
Factitious disorder with predominantly psychological signs and symptoms
300.19
Other and unspecified factitious illness
300.20
Phobia, unspecified
300.21
Agoraphobia with panic disorder
300.22
Agoraphobia without mention of panic attacks
300.23
Social phobia
300.29
Other isolated or specific phobias
F40.00
Agoraphobia, unspecified
F40.01
Agoraphobia with panic disorder
F40.02
Agoraphobia without panic disorder
F40.10
Social phobia, unspecified
F40.11
Social phobia, generalized
F40.210
Arachnophobia
F40.218
Other animal type phobia
F40.220
Fear of thunderstorms
F40.228
Other natural environment type phobia
F40.230
Fear of blood
F40.231
Fear of injections and transfusions
F40.232
Fear of other medical care
F40.233
Fear of injury
F40.240
Claustrophobia
F40.241
Acrophobia
F40.242
Fear of bridges
F40.243
Fear of flying
F40.248
Other situational type phobia
F40.290
Androphobia
F40.291
Gynephobia
F40.298
Other specified phobia
F40.8
Other phobic anxiety disorders
F40.9
Phobic anxiety disorder, unspecified
F41.0
Panic disorder [episodic paroxysmal anxiety] without agoraphobia
F41.1
Generalized anxiety disorder
F41.3
Other mixed anxiety disorders
F41.8
Other specified anxiety disorders
F41.9
Anxiety disorder, unspecified
Personality Disorders
301.0
Paranoid personality disorder
301.10
Affective personality disorder, unspecified
301.11
Chronic hypomanic personality disorder
301.12
Chronic depressive personality disorder
301.13
Cyclothymic disorder
301.20
Schizoid personality disorder, unspecified
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301.21
301.22
301.3
301.4
301.50
301.51
301.59
301.6
301.7
301.81
301.82
301.83
301.84
301.89
301.9
F60.0
F60.1
F60.2
F60.3
F60.4
F60.5
F60.6
F60.7
F60.81
F60.89
F60.9

Introverted personality
Schizotypal personality disorder
Explosive personality disorder
Obsessive-compulsive personality disorder
Histrionic personality disorder, unspecified
Chronic factitious illness with physical symptoms
Other histrionic personality disorder
Dependent personality disorder
Antisocial personality disorder
Narcissistic personality disorder
Avoidant personality disorder
Borderline personality disorder
Passive-aggressive personality
Other personality disorders
Unspecified personality disorder
Paranoid personality disorder
Schizoid personality disorder
Antisocial personality disorder
Borderline personality disorder
Histrionic personality disorder
Obsessive-compulsive personality disorder
Avoidant personality disorder
Dependent personality disorder
Narcissistic personality disorder
Other specific personality disorders
Personality disorder, unspecified
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